Sentence examples for difference in potency of from inspiring English sources

Sunitinib, a multi-kinase inhibitor with FLT3 but not JAK2 activity, showed a 14-fold difference in potency of MV4-11-P compared with MV4-11-R.

For MMP-cliffs, a difference in potency of at least two orders of magnitude between cliff-forming compounds was set as a potency difference criterion.

The difference in potency of 24F4A versus 24F4A-ef was not due to a difference in signaling downstream of BDCA2 engagement as 24F4A and 24F4A-ef were equally capable of inducing phosphorylation of Syk and PLCγ2 (Fig 4G).

The inhibition with hesperadin at 1 μM was less pronounced than for 1 μM barasertib, which may be explained by the difference in potency of the two inhibitors, IC50 for barasertib is 0.37 nM and for hesperadin 250 nM (see www.selleckchem.com).selleckchem.com

The differences at T=0 are not due to enrollment mistakes, but to: 1) the difference in potency of the drug used (ie, the effect of statins being more evident than the one exerted by ezetimibe) and 2) the subjects of the Berberol® alone group were still untreated at T=0.

Recently, Paolini et al. 6 mapped the human pharmacological interaction network using the definition that two proteins interact if they bind at least 10% of shared compounds with a difference in potency of only 10-fold below an activity cutoff of 10 μM, and applied it in network analysis of drug –target interactions associated with asthma.

The ideal measure of opioid use would be to report total milligrams of morphine equivalency, to capture not only differences in doses across opioid prescriptions but also differences in potency of different opioids.

The difference in potencies of the DKA inhibitors is thus attributed to the different binding modes at the catalytic site.

The difference in potencies of hydantoin and piperazinedione analogues, together with the necessity of C-5/C-6 R-absolute configuration has been revealed through molecular docking.

In addition, the difference in potencies of iAsIII and MAsIII to inhibit PDK-1 activity and ISGU may be in part due to differences in the uptake and/or retention of these arsenicals by adipocytes.

Thus differences in potency of the effects of the two different mitochondrial inhibitors in two cell types correlate with the difference in mitochondrial distribution described above.